ATE119037T1 - Influenzaimpfstoff und adjuvanten. - Google Patents

Influenzaimpfstoff und adjuvanten.

Info

Publication number: ATE119037T1
Authority: AT; Austria
Prior art keywords: antigen; present; dosage form; immunization dose; adjuvants
Prior art date: 1988-08-25

Application number

AT89402343T

Other languages

English (en)

Inventor

Mircea C Popescu

Marie S Recine

Carl L Alving

Leonard F Estis

Lynn D Keyes

Andrew S Janoff

Original Assignee

Liposome Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-08-25

Filing date

1989-08-25

Publication date

1995-03-15

1989-08-25 Application filed by Liposome Co Inc filed Critical Liposome Co Inc

1995-03-15 Application granted granted Critical

1995-03-15 Publication of ATE119037T1 publication Critical patent/ATE119037T1/de

Links

239000002671 adjuvant Substances 0.000 title 1
229960003971 influenza vaccine Drugs 0.000 title 1
239000000427 antigen Substances 0.000 abstract 6
102000036639 antigens Human genes 0.000 abstract 6
108091007433 antigens Proteins 0.000 abstract 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
230000003053 immunization Effects 0.000 abstract 4
239000002552 dosage form Substances 0.000 abstract 3
238000002649 immunization Methods 0.000 abstract 3
239000002502 liposome Substances 0.000 abstract 3
229930182558 Sterol Natural products 0.000 abstract 2
235000012000 cholesterol Nutrition 0.000 abstract 2
230000028993 immune response Effects 0.000 abstract 2
206010022000 influenza Diseases 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
150000007524 organic acids Chemical class 0.000 abstract 2
150000003432 sterols Chemical class 0.000 abstract 2
235000003702 sterols Nutrition 0.000 abstract 2
108010004032 Bromelains Proteins 0.000 abstract 1
101710154606 Hemagglutinin Proteins 0.000 abstract 1
101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 1
239000004365 Protease Substances 0.000 abstract 1
101710176177 Protein A56 Proteins 0.000 abstract 1
229940024546 aluminum hydroxide gel Drugs 0.000 abstract 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 abstract 1
235000019835 bromelain Nutrition 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000000185 hemagglutinin Substances 0.000 abstract 1
150000003839 salts Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Immunology (AREA)
Virology (AREA)
Oncology (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Manufacturing Of Micro-Capsules (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT89402343T 1988-08-25 1989-08-25 Influenzaimpfstoff und adjuvanten. ATE119037T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US23670288A	1988-08-25	1988-08-25
US23670188A	1988-08-25	1988-08-25
US39777789A	1989-08-23	1989-08-23

Publications (1)

Publication Number	Publication Date
ATE119037T1 true ATE119037T1 (de)	1995-03-15

Family

ID=27398905

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT89402343T ATE119037T1 (de)	1988-08-25	1989-08-25	Influenzaimpfstoff und adjuvanten.
AT94201844T ATE182080T1 (de)	1988-08-25	1989-08-25	Dosierungsform die ein antigen und eine salzform eines organischen säurederivats eines sterols enthält

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT94201844T ATE182080T1 (de)	1988-08-25	1989-08-25	Dosierungsform die ein antigen und eine salzform eines organischen säurederivats eines sterols enthält

Country Status (9)

Country	Link
EP (2)	EP0356339B1 (de)
JP (1)	JPH04500203A (de)
AT (2)	ATE119037T1 (de)
AU (2)	AU627226B2 (de)
CA (1)	CA1337332C (de)
DE (2)	DE68921389T2 (de)
ES (2)	ES2133477T3 (de)
GR (1)	GR3031244T3 (de)
NZ (2)	NZ241926A (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5985318A (en) *	1990-08-24	1999-11-16	Burroughs Wellcome Co.	Fusogenic liposomes that are free of active neuraminidase
GB9018690D0 (en) *	1990-08-24	1990-10-10	Wellcome Found	Vaccines
DK0538437T3 (da) *	1991-05-08	2000-02-07	Schweiz Serum & Impfinst	Immunstimulerende og immunforstærkende, rekonstituerede influenzavirosomer og vacciner indeholdende dem
US5879685A (en) *	1991-05-08	1999-03-09	Schweiz, Serum- & Impfinstitut Bern	Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU5420494A (en) *	1992-11-02	1994-05-24	Yves Claude Nicolau	Method of reducing multidrug resistance in cells and tissues
WO1994019013A1 (en) *	1993-02-19	1994-09-01	Smithkline Beecham Corporation	Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE69533693T2 (de) *	1994-02-24	2005-12-22	Novavax Inc.(n.d.Ges.d.Staates Delaware)	Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
FR2726764B1 (fr)	1994-11-14	1997-01-31	Pasteur Merieux Serums Vacc	Adjuvant pour composition vaccinale
US5919480A (en) *	1996-06-24	1999-07-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Liposomal influenza vaccine composition and method
HUE031886T2 (en)	2002-10-11	2017-08-28	Glaxosmithkline Biologicals Sa	Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
ES2461350T3 (es)	2003-01-30	2014-05-19	Novartis Ag	Vacunas inyectables contra múltiples serogrupos de meningococos
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
CN103357002A (zh)	2003-10-02	2013-10-23	诺华疫苗和诊断有限公司	多种脑膜炎球菌血清群的液体疫苗
WO2005107797A1 (en)	2004-03-09	2005-11-17	Chiron Corporation	Influenza virus vaccines
ATE512670T1 (de)	2004-04-30	2011-07-15	Novartis Vaccines & Diagnostic	Meningokokken-konjugat-impfung
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0410866D0 (en)	2004-05-14	2004-06-16	Chiron Srl	Haemophilius influenzae
US20090104226A1 (en)	2004-05-21	2009-04-23	Novartis Vaccines And Diagnostics Inc.	Alphavirus Vectors for Respiratory Pathogen Vaccines
EP1784211A4 (de)	2004-07-29	2010-06-30	Novartis Vaccines & Diagnostic	Immunogene zusammensetzungen für grampositive bakterien wie streptococcus agalactiae
GB0424092D0 (en)	2004-10-29	2004-12-01	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
NZ599345A (en)	2005-02-18	2013-07-26	Novartis Vaccines & Diagnostic	Immunogens from uropathogenic Escherichia Coli
AU2006214064B2 (en)	2005-02-18	2012-04-26	J. Craig Venter Institute, Inc.	Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CA2626253A1 (en)	2005-10-18	2007-04-26	Novartis Vaccines And Diagnostics, Inc.	Mucosal and systemic immunizations with alphavirus replicon particles
ES2420829T3 (es)	2005-11-04	2013-08-27	Novartis Vaccines And Diagnostics S.R.L.	Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
CA2630220C (en)	2005-11-22	2020-10-13	Doris Coit	Norovirus and sapovirus antigens
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
EP3753574A1 (de)	2006-01-27	2020-12-23	Seqirus UK Limited	Influenzaimpfstoffe mit hämagglutinin und matrixproteinen
CA2646539A1 (en)	2006-03-23	2007-09-27	Novartis Ag	Imidazoquinoxaline compounds as immunomodulators
CA2646891A1 (en)	2006-03-23	2007-09-27	Novartis Ag	Immunopotentiating compounds
EP2004226A1 (de)	2006-03-24	2008-12-24	Novartis Vaccines and Diagnostics GmbH & Co. KG	Lagerung von grippeimpfstoffen ohne kühlung
US20100285062A1 (en)	2006-03-31	2010-11-11	Novartis Ag	Combined mucosal and parenteral immunization against hiv
DK2054431T3 (da)	2006-06-09	2012-01-02	Novartis Ag	Konformere af bakterielle adhæsiner
AU2007258874B2 (en) *	2006-06-15	2013-11-14	Seqirus UK Limited	Adjuvant-sparing multi-dose influenza vaccination regimen
GB0614460D0 (en)	2006-07-20	2006-08-30	Novartis Ag	Vaccines
WO2008020330A2 (en)	2006-08-16	2008-02-21	Novartis Ag	Immunogens from uropathogenic escherichia coli
ES2536401T3 (es)	2006-09-11	2015-05-25	Novartis Ag	Fabricación de vacunas contra virus de la gripe sin usar huevos
SG177141A1 (en)	2006-12-06	2012-01-30	Novartis Ag	Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en)	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
EA201070066A1 (ru)	2007-06-27	2010-06-30	Новартис Аг	Вакцины против гриппа с низким содержанием добавок
GB0713880D0 (en)	2007-07-17	2007-08-29	Novartis Ag	Conjugate purification
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
CA2699513C (en)	2007-09-12	2018-03-13	Novartis Ag	Gas57 mutant antigens and gas57 antibodies
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PL2235046T3 (pl)	2007-12-21	2012-12-31	Novartis Ag	Zmutowane formy streptolizyny O
CN102356089B (zh)	2008-02-21	2014-02-19	诺华股份有限公司	脑膜炎球菌fHBP多肽
WO2009115917A2 (en)	2008-03-18	2009-09-24	Novartis Ag	Improvements in preparation of influenza virus vaccine antigens
CN102481349B (zh)	2009-01-12	2014-10-15	诺华股份有限公司	抗革兰氏阳性细菌疫苗中的Cna_B结构域
CA2754618A1 (en)	2009-03-06	2010-09-10	Novartis Ag	Chlamydia antigens
MX2011010735A (es)	2009-04-14	2012-01-25	Novartis Ag	Composiciones para inmunizacion contra staphylococcus aureus.
WO2010146414A1 (en)	2009-06-15	2010-12-23	National University Of Singapore	Influenza vaccine, composition, and methods of use
WO2011004263A2 (en)	2009-07-07	2011-01-13	Novartis Ag	Conserved escherichia coli immunogens
EP4218799A1 (de)	2009-07-15	2023-08-02	GlaxoSmithKline Biologicals S.A.	Rsv-f-proteinzusammensetzungen und verfahren zur herstellung davon
PL2464658T3 (pl)	2009-07-16	2015-03-31	Novartis Ag	Immunogeny z Escherichia coli o zniesionej toksyczności
US20110076300A1 (en)	2009-08-27	2011-03-31	Mariagrazia Pizza	Hybrid Polypeptides Including Meningococcal fHBP Sequences
CN102695523A (zh)	2009-09-10	2012-09-26	诺华有限公司	针对呼吸道疾病的组合疫苗
GB0917002D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Improved shigella blebs
GB0917003D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Purification of bacterial vesicles
US8974799B2 (en)	2009-09-30	2015-03-10	Novartis Ag	Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
CN102724988B (zh)	2009-09-30	2014-09-10	诺华股份有限公司	脑膜炎球菌fHBP多肽的表达
GB0918392D0 (en)	2009-10-20	2009-12-02	Novartis Ag	Diagnostic and therapeutic methods
CA2779816A1 (en)	2009-10-27	2011-05-05	Novartis Ag	Modified meningococcal fhbp polypeptides
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
JP5781542B2 (ja)	2009-12-30	2015-09-24	ノバルティスアーゲー	Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en)	2010-02-26	2010-04-14	Novartis Ag	Immunogenic proteins and compositions
GB201005625D0 (en)	2010-04-01	2010-05-19	Novartis Ag	Immunogenic proteins and compositions
BR112012025364A2 (pt)	2010-04-07	2015-09-22	Novartis Ag	método para geração de partícula semelhante a vírus de parvovírus b19
WO2011130379A1 (en)	2010-04-13	2011-10-20	Novartis Ag	Benzonapthyridine compositions and uses thereof
KR20130121699A (ko)	2010-05-28	2013-11-06	테트리스 온라인, 인코포레이티드	상호작용 혼성 비동기 컴퓨터 게임 기반구조
GB201009861D0 (en)	2010-06-11	2010-07-21	Novartis Ag	OMV vaccines
AU2011276328C1 (en)	2010-07-06	2016-01-21	Novartis Ag	Norovirus derived immunogenic compositions and methods
US9192661B2 (en)	2010-07-06	2015-11-24	Novartis Ag	Delivery of self-replicating RNA using biodegradable polymer particles
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
GB201017519D0 (en)	2010-10-15	2010-12-01	Novartis Vaccines Inst For Global Health S R L	Vaccines
CN102000332B (zh) *	2010-11-16	2012-07-04	南京农业大学	一种用于鸭禽流感口服黏膜免疫的复合佐剂
WO2012072769A1 (en)	2010-12-01	2012-06-07	Novartis Ag	Pneumococcal rrgb epitopes and clade combinations
WO2012085668A2 (en)	2010-12-24	2012-06-28	Novartis Ag	Compounds
AU2012211278B2 (en)	2011-01-26	2016-11-10	Glaxosmithkline Biologicals Sa	RSV immunization regimen
DK2707385T3 (da)	2011-05-13	2017-11-20	Glaxosmithkline Biologicals Sa	RSV-F-præfusionsantigener
US11058762B2 (en)	2011-07-06	2021-07-13	Glaxosmithkline Biologicals Sa	Immunogenic compositions and uses thereof
WO2013006838A1 (en)	2011-07-06	2013-01-10	Novartis Ag	Immunogenic combination compositions and uses thereof
WO2013009564A1 (en)	2011-07-08	2013-01-17	Novartis Ag	Tyrosine ligation process
US10030052B2 (en)	2011-07-25	2018-07-24	Glaxosmithkline Biologicals Sa	Parvovirus Vp1 unique region polypeptides and compositions thereof
GB201114923D0 (en)	2011-08-30	2011-10-12	Novartis Ag	Immunogenic proteins and compositions
WO2013038385A2 (en)	2011-09-14	2013-03-21	Novartis Ag	Escherichia coli vaccine combination
EP2755683B1 (de)	2011-09-14	2019-04-03	GlaxoSmithKline Biologicals SA	Verfahren zur herstellung von saccharidprotein-glykokonjugaten
EP2776069A1 (de)	2011-11-07	2014-09-17	Novartis AG	Trägermolekül mit einem spr0096- und einem spr2021-antigen
AU2012349753A1 (en)	2011-12-08	2014-06-19	Novartis Ag	Clostridium difficile toxin-based vaccine
WO2013108272A2 (en)	2012-01-20	2013-07-25	International Centre For Genetic Engineering And Biotechnology	Blood stage malaria vaccine
RU2014138418A (ru)	2012-02-24	2016-04-10	Новартис Аг	Белки пилей и композиции
CN104321078A (zh)	2012-04-26	2015-01-28	诺华股份有限公司	抗原和抗原组合
US10279026B2 (en)	2012-04-26	2019-05-07	Glaxosmithkline Biologicals Sa	Antigens and antigen combinations
WO2013174832A1 (en)	2012-05-22	2013-11-28	Novartis Ag	Meningococcus serogroup x conjugate
US20150140068A1 (en)	2012-07-06	2015-05-21	Novartis Ag	Immunogenic compositions and uses thereof
US9764027B2 (en)	2012-09-18	2017-09-19	Glaxosmithkline Biologicals Sa	Outer membrane vesicles
WO2014053521A2 (en)	2012-10-02	2014-04-10	Novartis Ag	Nonlinear saccharide conjugates
AR092897A1 (es)	2012-10-03	2015-05-06	Novartis Ag	Composiciones inmunogenicas
WO2015051122A2 (en) *	2013-10-02	2015-04-09	The Board Of Trustees Of The Leland Stanford Junior University	Wnt compositions and methods for purification
US10821175B2 (en)	2014-02-25	2020-11-03	Merck Sharp & Dohme Corp.	Lipid nanoparticle vaccine adjuvants and antigen delivery systems
CN104535017B (zh) *	2014-12-19	2017-11-21	合肥市百胜科技发展股份有限公司	在线轮廓测量装置
IL246378A0 (en) *	2016-06-21	2016-11-30	Technion Res & Dev Foundation	A hybrid matrix of polymers that adhere to the mucosa and a lipidic drug release system for the treatment of oral cancer
EP3939604A3 (de) *	2016-10-21	2022-06-22	Merck Sharp & Dohme Corp.	Influenza-hämagglutinin-protein-impfstoffe
WO2019145950A1 (en)	2018-01-23	2019-08-01	Technion Research & Development Foundation Limited	Collagenase loaded liposomes for enhancing drug delivery
WO2020039033A1 (en)	2018-08-23	2020-02-27	Glaxosmithkline Biologicals Sa	Immunogenic proteins and compositions
CN115175924A (zh)	2020-02-26	2022-10-11	港大科桥有限公司	基于pd-1的针对冠状病毒感染的疫苗
WO2022234483A1 (en)	2021-05-04	2022-11-10	King Abdullah University Of Science And Technology	Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
WO2023079529A1 (en)	2021-11-05	2023-05-11	King Abdullah University Of Science And Technology	Re-focusing protein booster immunization compositions and methods of use thereof
WO2023079528A1 (en)	2021-11-05	2023-05-11	King Abdullah University Of Science And Technology	Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
AU2023238223A1 (en)	2022-03-23	2024-10-10	Nanovation Therapeutics Inc.	High sterol-containing lipid nanoparticles
CN119654166A (zh)	2022-04-01	2025-03-18	内诺维什疗法股份有限公司	mRNA递送方法及其组合物
EP4558169A1 (de)	2022-07-22	2025-05-28	Institut National de la Santé et de la Recherche Médicale	Verwendung von bordetella-stämmen zur behandlung von chronisch obstruktiver lungenerkrankung
EP4633671A1 (de)	2022-12-14	2025-10-22	Yale University	Zusammensetzungen und verfahren zur verwendung davon zur behandlung von virenbedingten krebs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1502774A (en) *	1974-06-25	1978-03-01	Nat Res Dev	Immunological preparations
US4148876A (en) *	1975-09-29	1979-04-10	Burroughs Wellcome Co.	Biological preparations
US4201767A (en) *	1978-11-08	1980-05-06	Merck & Co., Inc.	Viral liposome particle
US4522811A (en) *	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4721612A (en) *	1984-04-12	1988-01-26	The Liposome Company, Inc.	Steroidal liposomes
US4891208A (en) *	1985-04-10	1990-01-02	The Liposome Company, Inc.	Steroidal liposomes
JPH0688911B2 (ja) *	1985-06-06	1994-11-09	国立予防衛生研究所長	インフルエンザワクチン及びその製造方法

1989
- 1989-08-24 NZ NZ241926A patent/NZ241926A/xx unknown
- 1989-08-24 NZ NZ230423A patent/NZ230423A/en unknown
- 1989-08-24 JP JP1509162A patent/JPH04500203A/ja active Pending
- 1989-08-24 AU AU41861/89A patent/AU627226B2/en not_active Ceased
- 1989-08-24 AU AU42214/89A patent/AU631377B2/en not_active Ceased
- 1989-08-25 ES ES94201844T patent/ES2133477T3/es not_active Expired - Lifetime
- 1989-08-25 EP EP89402343A patent/EP0356339B1/de not_active Expired - Lifetime
- 1989-08-25 DE DE68921389T patent/DE68921389T2/de not_active Expired - Fee Related
- 1989-08-25 ES ES89402343T patent/ES2069600T3/es not_active Expired - Lifetime
- 1989-08-25 DE DE68929033T patent/DE68929033T2/de not_active Expired - Fee Related
- 1989-08-25 CA CA000609464A patent/CA1337332C/en not_active Expired - Fee Related
- 1989-08-25 AT AT89402343T patent/ATE119037T1/de not_active IP Right Cessation
- 1989-08-25 AT AT94201844T patent/ATE182080T1/de not_active IP Right Cessation
- 1989-08-25 EP EP94201844A patent/EP0626169B1/de not_active Expired - Lifetime
1999
- 1999-09-16 GR GR990402336T patent/GR3031244T3/el unknown

Also Published As

Publication number	Publication date
GR3031244T3 (en)	1999-12-31
EP0626169B1 (de)	1999-07-14
AU4186189A (en)	1990-03-23
ES2133477T3 (es)	1999-09-16
EP0356339A1 (de)	1990-02-28
EP0356339B1 (de)	1995-03-01
ES2069600T3 (es)	1995-05-16
CA1337332C (en)	1995-10-17
NZ241926A (en)	1993-08-26
NZ230423A (en)	1993-08-26
EP0626169A3 (de)	1995-12-13
AU631377B2 (en)	1992-11-26
DE68929033T2 (de)	1999-12-30
DE68921389D1 (de)	1995-04-06
DE68929033D1 (de)	1999-08-19
JPH04500203A (ja)	1992-01-16
DE68921389T2 (de)	1995-06-29
AU4221489A (en)	1990-03-23
ATE182080T1 (de)	1999-07-15
AU627226B2 (en)	1992-08-20
EP0626169A2 (de)	1994-11-30

Legal Events

Date	Code	Title	Description
1995-07-15	UEP	Publication of translation of european patent specification
2000-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE119037T1 (de)	1995-03-15	Influenzaimpfstoff und adjuvanten.
Isaka et al.	2001	Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant
NO954786L (no)	1996-01-23	Hjelpestoffer for vaksiner mot åndedretts-syncytalvirus
DE69739253D1 (de)	2009-03-26	Liposomaler grippeimpfstoff und verfahren
DE69332518D1 (de)	2003-01-09	Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
NO20021431L (no)	2002-04-24	Intranasal influensavirus vaksine
CY1107571T1 (el)	2013-03-13	Αυξητικος παραγοντας νευρων ως βοηθητικη ουσια εμβολιου
CA2022420A1 (en)	1991-02-19	Escherichia coli vaccine
BR9506885A (pt)	1997-08-19	Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
AR036315A1 (es)	2004-08-25	Vacuna para la aterosclerosis con fragmentos de apociii, anticuerpos anti apociii
ATE157258T1 (de)	1997-09-15	Zubereitungen und behandlungen von pneumonia in tieren
FI875015A0 (fi)	1987-11-13	Vaccin mot juverinflammation.
FI932759A0 (fi)	1993-06-16	Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
EP0268640A4 (de)	1989-11-30	Impfstoff zur stimulierung oder erhöhung von antikörpern gegen gm2.
NO890565L (no)	1989-02-09	Forhindring og behandling av retroviral sykdom.
AU6435596A (en)	1996-11-07	Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
Oberling et al.	1985	Enhancement of antibody response to a natural fragment of streptococcal M protein by Murabutide administered to healthy volunteers
ZA881081B (en)	1988-08-11	Virus antigen,method for its preparation and its use for diagnostic and therapeutic purposes(vaccines)
DK0542895T3 (da)	1997-05-12	Krydsreaktiv influenza A immunisering
Chedid et al.	1985	Production of biologically active anti-peptide antibodies in human volunteers immunized with a synthetic peptide of streptococcus pyogenes type 24 M protein
Jolivet et al.	1985	Antibody response and protective activity with a new synthetic polyvalent vaccine
SE8400934D0 (sv)	1984-02-21	Forfarande for framstellning av lyofiliserade, adsorberade, polyvalenta vacciner
RU2002102482A (ru)	2003-10-10	Способ иммунизации стельных коров для профилактики вирусной диареи-болезни слизистых у телят